NY Mesothelioma Lawyer Says ‘Organ-On-A-Microchip’ Research is ‘Exciting’ Development
New York, NY, August 25, 2012 — New York mesothelioma attorney Joseph W. Belluck today commented on a recent National Public Radio report about the development of microchips that mimic human organs such as the lungs.
Belluck said the microchips may mark a promising advance toward better understanding and treatment of mesothelioma.
“According to the report, these microchips could ultimately be used to produce faster results for drug testing, and that is certainly an exciting development. Faster results are particularly important to mesothelioma sufferers, since the disease is so aggressive once it takes hold,” Belluck said.
Belluck is a partner in the New York personal injury firm of Belluck & Fox, LLP, which has been nationally recognized for its legal work on behalf of mesothelioma victims. The firm has also been an active supporter of research into improved care and treatment for mesothelioma sufferers, particularly the work in gene therapy being done by Dr. Harvey Pass and the NYU Langone Medical Center’s Cancer Institute.
National Public Radio’s “Science Friday” program recently reported on the work being done at Harvard University’s Wyss Institute for Biologically Inspired Engineering to develop the microchips, which mimic various human organs.
Clear, flexible polymer chips, about the size of a memory stick, are lined by living human cells and replicate the responses of living organs. A microchip-based lung, for example, expands and contracts like a breathing lung.
Researchers can watch a diseased microchip lung’s inner-workings as fluids build up and shift or as blood clots form, Donald Ingber, director of the Wyss Institute, told the NPR program. As drugs are introduced, lung cells react right before researchers’ eyes.
A five-year grant from the Defense Advanced Research Projects Agency (DARPA) will allow researchers to link microchip organs to create a fuller human system to examine the body’s multiple reactions to a single drug.
Ingber explained that therapies proven successful in animals often do not translate to human tests because humans metabolize drugs differently. Use of synthetic human organs will eliminate these failures.
“We’re hopeful this technology could one day be used to help those who suffer from mesothelioma and other asbestos-related diseases,” Belluck said.
The firm’s New York City office is located at 546 Fifth Ave, 4th Floor, New York, NY 10036 (local phone (212) 681-1575). For more information, contact the firm at 877-MESOTHELIOMA (637-6843) or through its online contact form.